COCP - CIK 0001412486
Cocrystal Pharma, Inc. (COCP) reported net income of -$8.83M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$8.83M | +49.5% |
| FY 2024 | -$17.50M | +2.7% |
| FY 2023 | -$17.98M | +53.7% |
| FY 2022 | -$38.84M | -173.8% |
| FY 2021 | -$14.19M | -47.0% |
| FY 2020 | -$9.65M | +80.0% |
| FY 2019 | -$48.17M | +1.8% |
| FY 2018 | -$49.05M | -7901.3% |
| FY 2017 |
Cocrystal Pharma, Inc. (COCP) reported net income of -$8.83M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2011 and fiscal 2025, Cocrystal Pharma, Inc.'s net income declined from -$5.46M to -$8.83M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| -$613.00K |
| +99.2% |
| FY 2016 | -$74.87M | -49.4% |
| FY 2015 | -$50.12M | -50528.3% |
| FY 2014 | -$99.00K | +97.5% |
| FY 2013 | -$3.89M | +51.2% |
| FY 2012 | -$7.96M | -45.9% |
| FY 2011 | -$5.46M | - |